Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib monotherapy in recent HIV-1 infection
2021-001288-26Phase 2Active
- Sponsor
- August Pi i Sunyer Biomedical Research Institute
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of dasatinib in human immunodeficiency virus infection (HIV), sponsored by August Pi i Sunyer Biomedical Research Institute. Primary endpoint: Safety and tolerability of dasatinib with and without antiretroviral therapy. Started Apr 2022; status: active.
02
Drugs
dasatinib
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2021-001288-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001288-26.